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Abstract
Purpose N-(4-[18F]Fluorobenzoyl)interleukin-2 ([18F]FB-
IL2) specifically binds to interleukin-2 receptors (IL-2R)
and thus may be used to detect inflammation processes
using positron emission tomography (PET). We now vali-
dated whether [18F]FB-IL2 can be used to quantify activated
human peripheral blood mononuclear cells (hPBMC) in rats
by pharmacokinetic modelling.
Methods Eleven Wistar rats were subcutaneously inoculated
in the shoulder with different amounts of phytohaemaggluti-
nin (PHA) activated hPBMC 15 min before i.v. injection of
[18F]FB-IL2. A 60-min dynamic PET scan was acquired and
arterial blood sampling and metabolite analysis were per-
formed. At the end of the scan, animals were terminated and
the inflammatory lesion dissected. PET data were analysed
using Logan and Patlak analysis as well as one-tissue and two-
tissue compartment models. Model preferences according to
the Akaike information criterion (AIC) and correlation
between PET measurements and the number of CD25-
positive cells were evaluated.
Results A high correlation between ex vivo tracer uptake
(standardized uptake value) in the xenograft and the number
of inoculated CD25-positive cells was observed (R200.90).
Plasma time-activity curves showed a rapid washout of the
radiopharmaceutical from blood, while the time-activity
curves of the inflammatory lesions showed slower washout.
Time-activity curves could be fitted well by the Logan
analysis method, indicating that the binding between [18F]
FB-IL2 and CD25 is reversible. AIC indicated that data
could be modelled best by a two-tissue reversible compart-
ment model. A high correlation was observed between the
binding potential and the number of CD25-positive cells
(R200.876, p<0.0001). Based on binding potential mea-
sured by PET, the limit of detection was about 160,000
CD25-positive cells per 200 μl lesion (95 % confidence).
Conclusion [18F]FB-IL2 kinetics in this animal model of
inflammation could be best described by a reversible two-
tissue compartment model. The [18F]FB-IL2 binding poten-
tial is a suitable measure for accurate quantification of lym-
phocytic infiltration in pathological conditions with PET.
Keywords Pharmacokinetics . [18F]FB-IL2 . Molecular
imaging . Inflammation
Introduction
High levels of interleukin-2 receptors (IL-2R) can be found
mainly on the surface of activated T lymphocytes (both CD4+
and CD8+, mainly Th1 lymphocytes) [1–3] after endogenous
stimulation. T lymphocytes are activated by inflammatory
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processes, such as tissue degeneration [4–6], autoimmune
diseases [7, 8], viral, fungal and mycobacterial infections,
graft rejection and in tumour infiltrates [9–15]. These disor-
ders are characterized by the activation of the immune
system and slow recruitment of immune cells (peripher-
al blood mononuclear cell, PBMC) in the lesion. The
infiltration of PBMC in the inflammatory lesion is the
histopathological hallmark of chronic inflammation, in
contrast to the granulocyte infiltration found in acute
inflammatory conditions. During activation, immune
cells overexpress multimeric IL-2R, which are able to
sustain immune cell proliferation and cell survival. The
IL-2R consists of three subunits (α, β and γ chains,
called CD25, CD122 and CD132, respectively). CD25
contains the main binding site for IL-2 and can be
present as a transmembrane or soluble receptor. Because
IL-2R expression is low in resting immune cells, the
receptor might be a suitable biomarker to study active
inflammation in chronic inflammatory diseases.
Since IL-2 is the natural ligand of the IL-2R, this
glycoprotein was selected as a potential radiopharma-
ceutical for imaging activated T lymphocytes [16]. In
the past, IL-2 was labelled with various isotopes for
single proton emission computed tomography (SPECT)
imaging [17–21]. The labelled IL-2 derivatives showed
good results in terms of localization of the inflammation
within the limitations of gamma camera imaging. Label-
ling with a suitable positron emission tomography (PET)
isotope may improve sensitivity of this radiopharmaceu-
tical and therefore N-(4-[18F]fluorobenzoyl)interleukin-2
([18F]FB-IL2) was developed by our group. In our pre-
vious studies, we demonstrated the ability of [18F]FB-
IL2 to selectively detect activated human peripheral
blood mononuclear cells (hPBMC) in rodent models of
inflammation by noninvasive PET imaging [22]. In ad-
dition, [18F]FB-IL2 was able to detect insulitis, a chron-
ic inflammatory process that precedes the clinical onset
of type 1 diabetes, in diabetes-prone rats and mice (data
submitted for publication).
The detection of chronic inflammation is important
for diagnostic, prognostic purposes and for monitoring
the disease progression and the efficacy of treatment. To
this end, quantitative measurement of the extent of
lymphocytic infiltration is required. In the present study
we aimed to investigate whether [18F]FB-IL2 PET is
able to quantify the amount of activated lymphocytes
in infiltrated tissue. For this purpose, pharmacokinetic
modelling was performed. Wistar rats were subcutane-
ously inoculated with activated hPBMC and subsequent-
ly studied with [18F]FB-IL2 microPET. Dynamic PET
data were analysed using various kinetics modelling




[18F]FB-IL2 was synthesized as described elsewhere [22].
[18F]FB-IL2 was obtained in 25 % radiochemical yield
based on succinimidyl 4-[18F]fluorobenzoic acid ([18F]
SFB) (corrected for the decay), with a specific activity of
117±6 GBq/μmol at the end of synthesis and with a radio-
chemical purity >95 %.
hPBMC activation and FACS analysis
Human blood was obtained from the local blood bank.
hPBMC were isolated from human peripheral blood by
density gradient medium centrifugation (Lymphoprep,
Axis-Shield) using the rapid centrifugation procedure devel-
oped by Bøyum [23, 24]. Cells were kept in RPMI 1640
supplemented with L-glutamine, 10 % fetal calf serum
(FCS), 100 IU penicillin/ml and 100 μg streptomycin/ml
(all from GIBCO). Isolated hPBMC were incubated for 48 h
with 5 μg/ml of phytohaemagglutinin (PHA-P, Sigma-
Aldrich) at 37 °C and 5 % CO2 for cell activation. At the
day of the microPET scan, overexpression of CD25 was
determined by fluorescence-activated cell sorting (FACS)
analysis. For this purpose, the cultured activated hPBMC
were washed once with 3 ml of cold phosphate-buffered
saline (PBS) and resuspended in PBS at a concentration of
106 cells/ml. Aliquots (0.1 ml) of the cell suspension were
incubated for 45 min in ice with PE-CD25 antibody or PE-
IgG antibody (E-Bioscience) as controls. After being
washed twice in 3 ml of cold PBS, the cells were
resuspended in 0.5 ml of FACS solution (PBS supplemented
with 5 % FCS) immediately prior to analysis using a FACS
Calibur (BD Biosciences). FACS data were analysed using
Winlist 5.0 software (Verity Software House) in order to
determine the percentage of CD25-expressing cells in each
sample.
Animals
All animal experiments were carried out according to the
Dutch Regulations for Animal Welfare. The protocol was
approved by the Ethics Committee of the University of
Groningen (protocol number: 5705 C).
After arrival, 11 Wistar rats (Charles River, The Nether-
lands) were acclimatized for at least 7 days. The animals
were housed in Makrolon cages on a layer of wood shavings
in a room with constant temperature (21±2 °C) and 12-h
light-dark regime. Commercial chow and tap water were
available ad libitum. All rats were subcutaneously implanted
with an increasing number of activated hPBMC in 100 μl
PBS mixed with 100 μl of Matrigel (Becton Dickinson, The
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Netherlands). The activated cells were inoculated in the
right shoulder of the animal 15 min before the PET
experiment.
PET acquisition protocol and arterial blood sampling
Rats were anaesthetized with 2% isoflurane in medical air and
a cannula for blood sampling was surgically inserted in the
femoral artery. The animals were placed in a transaxial posi-
tion in the PET camera (microPET Focus 220, Siemens/Con-
corde) with the shoulders of the rats in the field of view. Rats
were injected trough the penile vein with 17.1±1.2 MBq of
[18F]FB-IL2 and a dynamic PET scan was immediately ac-
quired for 60 min. After the emission scan, a transmission
scan of 515 s with a 57Co point source was obtained for the
correction of tissue attenuation. Two animals were scanned
simultaneously in each scan session. Arterial blood was
sampled during the course of the scan at 15, 30, 45, 60, 75,
90, 120, 180, 300, 450, 600, 900, 1,800 and 3,600 s after
tracer injection.When a blood sample was collected, 0.1 ml of
heparinized saline was injected via the artery cannula to
prevent large changes in blood pressure. Blood samples were
used to measure the plasma radioactivity concentration. Blood
was centrifuged (5 min at 13,000 rpm) to separate cells from
plasma. Then, 50 μl of each plasma sample was collected and
the activity in these plasma samples was measured with a
gamma counter (LKB Wallac, Turku, Finland). Plasma activ-
ity was corrected for decay.
Radiometabolite analysis in rat plasma and urine
Radiometabolite analysis of rat plasma was performed in a
separate study in rats without hPBMC lesion. Arterial blood
samples were collected at 1, 10, 20, 30, 40 and 60 min after
administration of 32.1±9.8 MBq [18F]FB-IL2. Blood was
centrifuged for 5 min at 13,000 rpm to separate the cells from
the plasma fraction. After centrifugation, 5 μl of each plasma
sample was spotted onto a thin-layer chromatography (TLC)
plate (Merck F-254 silica gel strip). The strip was eluted at
room temperature with ethyl acetate/n-hexane (3:1). [18F]SFB
migrated with the solvent front (Rf01), and [
18F]FB-IL2
remained at the origin (Rf00). The degradation product 4-
[18F]fluorobenzoic acid ([18F]FBA) has an Rf00.7. Detection
of the reference compounds on the TLC plates was performed
by UV light (254 nm). For radiolabelled compounds, the
detection on the TLC was performed by phosphor storage
imaging (multisensitive screens, Packard). These screens were
exposed to the TLC strips for a few minutes and subsequently
read out using a Cyclone phosphor storage imager
(PerkinElmer, USA) and analysed with OptiQuant software.
An additional 0.2 ml plasma sample obtained at 60 min
was filtered through a Vivaspin filter with a 30 kDa cutoff;
0.1 ml of this filtrate was analysed by analytical HPLC for the
identification of the radioactive metabolites. HPLC analyses
were carried out with Elite LaChrom Merck Hitachi L-7100
pump system using Luna C18-column (5 μm, 4.6×250 mm)
equippedwith both UV (Elite LaChromVWRHitachi L-2400
UV detector set at 254 nm) and a Bicron radioactivity monitor.
Gradient elution was performed using a mixture of 0.1 %
aqueous trifluoroacetic acid (solvent A) and 0.1 % trifluoro-
acetic acid in acetonitrile (solvent B). The following gradient
profile was used: 0–5 min 0 % B, 5–10 min 40 % B, 10–
35 min 65 % B, 35–45 min 100 % B and 45–47 min 0 % B at
flow rate of 1 ml/min. Retention times were: 24 min for [18F]
FB-IL2, 26 min for [18F]FBA and 30 min for [18F]SFB. The
same HPLC procedure was applied to analyse urine samples
for the formation of radioactive metabolites, using samples
collected 60 min after tracer injection.
Ex vivo biodistribution
After the PET scan, Wistar rats were sacrificed by extirpa-
tion of the heart while under deep anaesthesia. The xeno-
graft consisting of Matrigel mixed with inoculated cells was
dissected and weighed. As a reference tissue muscle from
the contralateral shoulder was isolated. Radioactivity in
each sample was measured by an automated gamma counter
(LKB Wallac, Turku, Finland). Radioactivity accumulation
in the target lesion was expressed as standardized uptake
value (SUV), using the formula: [(tissue activity concentra-
tion (MBq/g)]/[(injected dose (MBq)/body weight (g)].
Image reconstruction
All emission scans were normalized and corrected for random
coincidences, dead time, scatter, attenuation and decay. Emis-
sion sinograms were reconstructed using an ordered subset
expectation maximization (OSEM) algorithmwith 4 iterations
and 16 subsets. Three-dimensional regions of interest (3-D
ROIs) were generated automatically based on an intensity
threshold method using Inveon Research Workplace software
(Inveon, Siemens, USA). Briefly, all frames (0-60 min) were
summed and an ROI of the inflammatory region was gener-
ated automatically with a 50 % threshold using a region
growing method, i.e. only pixels were included with tracer
uptake greater than 50 % of the maximum value within the
lesion. The resulting ROIs were used on the original data set to
create the corresponding time-activity curves (TACs) using
standard software (Inveon, Siemens, USA).
Kinetic analysis
Pharmacokinetic modelling of the tissue TACs was performed
using standard software (Inveon, Siemens, USA). Graphical
Logan analysis and Patlak analysis were used to determine the
volume of distribution (Vd). Two compartmental models were
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used to fit ROI data. These were a reversible one-tissue com-
partment model (1TCMR, one tissue compartment with two
kinetic rate constants) and a reversible two-tissue compartment
model (2TCMR, two tissue compartments with four kinetic
rate constants). The blood pool compartment was considered
as the input function using the present terminology [25]. Best-
fit analysis was used to calculate the Vd and with the latter
model also the binding potential (BP). Vd is defined as K1/k2
for the 1TCMR and (K1/k2)(1+BP) for the 2TCMR, with the
BP being equal to k3/k4. The optimalmodel was selected based
on the Akaike information criterion (AIC) values generated by
the analysis software. AIC selects the model with the best fit of
the data, taking into account the number of fitted data points
and the number of fitted parameters [26].
Limit of detection
To assess the sensitivity of the PET method, the limit of
detection (LOD) for CD25-positive cells was determined by
measuring the BP of [18F]FB-IL2 in the contralateral shoul-
der (control). For this purpose, the ROI that was generated
for the inflammatory lesion at the injection site was copied
to the contralateral unaffected shoulder. The LOD was
defined as the mean of the BP in the control tissue + 2 times
the standard deviation in order to assure with 95 % confi-
dence that a signal at the inflammatory lesion was not due to
statistical variability. Subsequently, the LOD was applied to
calculate the minimum number of CD25-positive cells that
can be detected with [18F]FB-IL2, using the correlation
between the number of CD25-positive cells and the BP
(Fig. 7).
Statistical analysis
All data are expressed as mean ± standard deviation. Corre-
lations were calculated with the linear regression algorithm
in Sigma Plot and were considered statistically significant
whenever R2>0.5 and p<0.05.
Results
FACS analysis
The percentage of CD25-positive cells was calculated on the
day of the microPET experiment. PHA-P caused variable
stimulation of overexpression of CD25 on the cell surface of
hPBMC. The fraction of activated cells ranged between 5.5
and 9.9 %. The number of the inoculated hPBMC was
corrected for the fraction of CD25-positive cells before
correlation with the PET results. The number of CD25-
positive cells injected in the shoulder of the rats ranged from
0.17×106 to 1.9×106.
Ex vivo measurement of tracer accumulation
For comparison with the PET studies, ex vivo measurement
of radioactivity accumulated in the inflammatory lesion was
performed. The radiopharmaceutical uptake of the dissected
Matrigel + hPBMC was calculated in ten animals. In one
animal, the ex vivo tracer accumulation could not be deter-
mined due to an experimental error during dissection and
only kinetic modeling was performed in this animal. Muscle
in the shoulder contralateral with respect to the site of
hPBMC inoculation was used as a control tissue. As shown
in Fig. 1, there is a strong correlation between [18F]FB-IL2
uptake and the number of inoculated activated CD25+ cells
(R200.90, p value <0.0001). As expected, no correlation
was found between muscle uptake and number of inoculated
cells (R200.13, p value00.31).
Small animal PET imaging
At 60 min after intravenous injection of [18F]FB-IL2, acti-
vated hPBMC could be clearly visualized in the right shoul-
der of all animals (Fig. 2). By applying 50 % of SUVmax as
the threshold, an ROI was obtained for the inflammatory
lesions. SUV values of [18F]FB-IL2 were calculated for
each animal and were correlated with the number of
CD25-positive cells in the inflamed region. As shown in
Fig. 3, there was a moderate correlation between the cell
number and the SUV of [18F]FB-IL2 PET (R200.56,
p00.008).
[18F]FB-IL2 kinetics
Figure 4a shows the blood clearance of [18F]FB-IL2. Biex-
ponential curve-fitting analysis of [18F]FB-IL2 blood
Fig. 1 Correlation between [18F]FB-IL2 uptake (ex vivo SUV) and the
number of CD25+ cells in the inflammatory lesion (closed symbols)
and in muscle as a reference tissue (open symbols). R200.90,
p<0.0001, y00.14x−0.006 and R200.13, p00.31, y00.005x+0.013
for the inflammatory lesion and muscle, respectively
1554 Eur J Nucl Med Mol Imaging (2012) 39:1551–1560
clearance showed a two-phase blood clearance with 25±
11 % of the injected activity having a half-clearance time of
0.71±0.29 min and 75±11 % of the injected activity having
a half-clearance time of 8.4±2.6 min. Figure 4b shows the
average TAC for the inflammatory lesion in the animals
inoculated with approximately 106 CD25-positive hPBMC.
In contrast to plasma, the clearance from the cell inoculation
site is slower and it can be described by a one-phase curve
(0–60 min) with a half-clearance time of 37±4 min.
Metabolite analysis
Metabolites in plasma were analysed by TLC and by HPLC.
TLC analysis did not show any formation of hydrophobic
metabolites or formation of [18F]FBA (hydrolysis product).
HPLC analysis confirmed that at 60 min post-injection
(p.i.), the fraction of intact [18F]FB-IL2 in plasma was still
97.7±1.2 %. Urine samples were analysed as well.
After 60 min of tracer distribution, the main excretion prod-
uct is an unknown hydrophilic degradation product of [18F]
FB-IL2 with a retention time of 22 min. [18F]FBA and [18F]
FB-IL2 (26 and 24 min, respectively) were not found in the
urine. Because of the high stability of the tracer in plasma,
the total activity in plasma without correction for metabo-
lites was used as input function for the pharmacokinetic
modelling study.
Pharmacokinetic modelling
Pharmacokinetic modelling using the [18F]FB-IL2 TACs at
the inoculation site from 0 to 60 min after tracer injection
showed a significantly better fit (p<0.0001) using Logan
graphical analysis (R200.97±0.02) than with Patlak analysis
(R200.81±0.12). In addition, Logan analysis required a delay
time of only 3 min, whereas for Patlak analysis a delay time of
15 min had to be applied to obtain a reasonable fit (Fig. 5).
This suggests that the binding between the fluorinated IL-2
and CD25 is better described by a reversible model.
Next, the distribution volume was calculated by Logan
graphical analysis and compartment analysis using a 1TCMR
and a 2TCMR model. Correlation between the number of
CD25+ cells and the distribution volume are displayed in
Fig. 6. The distribution volume showed amoderate correlation
with the number of CD25+ cells when either Logan analysis
or compartment analysis with a 1TCMR or 2TCMR model
was used (R200.59, 0.59 and 0.52, respectively).
The model of preference for compartment modelling was
selected based on AIC values. The AIC values are 273±16
and 241±23 for 1TCMR and 2TCMR, respectively, with a
highly significant difference between those models
(p00.0011). Thus, TACs could be fit best using a 2TCMR
model. In contrast to the distribution volume and the
SUV, the BP is only dependent on the receptor binding
characteristics of the radiopharmaceutical. To exclude
any influence of differences in perfusion between ani-
mals, BP were calculated using the 2TCMR model. The
number of CD25-positive cells and the corresponding
BP values are plotted in Fig. 7. The BP is 0.45 for the
Fig. 2 Small animal PET images of [18F]FB-IL2 in the inflammatory
lesion of a rat inoculated with 0.99×106 CD25+ cells. Coronal (a),
sagittal (b) and transaxial (c) views of the thorax/abdomen of the rat.
The inflammatory lesion is indicated by a red arrow. The image
represents uptake in the inflammatory lesion from 0 to 60 min after
injection of [18F]FB-IL2. In the transverse image, the submandibular
glands are also visible
Fig. 3 Correlation between PET imaging-derived [18F]FB-IL2 uptake
expressed as SUV and the number of CD25+ cells present in the
inflamed region. (R200.56, p00.008, y00.07x+0.17)
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lesion with 0.17×106 CD25-positive cells and gradually
increases up to 7.44 for the lesion with 1.9×106 CD25+
cells. The BP increases by a factor of 4 for each million
cells preset in the inflammatory lesion. There is a strong
correlation between the BP and the number of CD25-
positive cells (R2 0.88, p<0.0001).
Fig. 4 [18F]FB-IL2 time-activity curves a for plasma and b for the inflamed region (mean ± standard deviation of animals injected with 106 CD25+
human activated PBMC)
Fig. 5 Representative Logan and Patlak graphical analysis for the inflamed region. a Logan graphical analysis showing a good fit of the inflamed
region from 3 min after [18F]FB-IL2 injection, whereas b Patlak graphical analysis shows a delay time of 15 min
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Limit of detection
To assess the sensitivity of [18F]FB-IL2, the LOD was deter-
mined bymeasuring the background signal in the contralateral
untreated shoulder. The average BP of [18F]FB-IL2 in the
contralateral shoulder was 0.42±0.20. Using a 95 % confi-
dence interval, the LOD can be defined as the average back-
ground signal plus 2 standard deviations. In this model, the
LOD of [18F]FB-IL2 would therefore be equal to 0.82. Using
the equation for the correlation between the BP and the
number of CD25-positive hPBMC (Fig. 7), we calculated that
the lowest number of CD25-positive cells that can be reliably
(95 % confidence) detected by this methods is approximately
160,000 cells in a lesion with a volume of 200 μl.
Discussion
The present investigation aims to demonstrate that [18F]FB-
IL2 PET imaging is a suitable tool to quantify lymphocyte
infiltration in tissues. In this study, pharmacokinetic analysis
of [18F]FB-IL2 was carried out in a rat xenograft model of
inflammation. Different parametric methods were used to
investigate which method was best to quantitatively mea-
sure activated immune cell infiltration.
Fig. 6 Correlation between the volume of distribution (Vd) determined
by a Logan analysis, b 1TCMR and c 2TCMR and the number of
CD25-positive cells. R2 was 0.59, p00.006, y00.32x+0.49 for Logan
analysis. R2 was 0.59, p00.005, y00.34x+0.48 for 1TCMR, and R2
was 0.52, p00.013, y00.32 x+0.56 for 2TCMR
Fig. 7 Correlation between the binding potential and the number of
CD25-positive cells. R2 0.88, p<0.0001, y04.06x+0.17
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Wistar rats inoculated with different numbers of human
activated PBMC were selected as the animal model of choice.
The big advantage of this animal model is the possibility to
determine the exact number of inoculated CD25-positive tar-
get cells by measuring PHA-P-induced CD25 expression
using FACS analysis. PHA-P is a strong activator of hPBMC.
One of the most important markers of this activation process is
the alpha subunit of the IL-2R (CD25). PHA-P-mediated cell
activation depends on several factors such as time of incuba-
tion and amount of hPBMC in culture. Moreover, hPBMC
derived from different healthy subjects show different predis-
position to the activation. In this study, hPBMC were isolated
from blood obtained from the local blood bank. hPBMC in
these samples are less prone to activation by PHA-P than
freshly isolated hPBMC from peripheral blood. Consequently,
the fraction of CD25-expressing cells in the cell cultures was
relatively low in this study, but the experimental design of this
study allowed us to correct the data for the exact number of
CD25-positive cells inoculated in the inflammatory lesion.
Ideally, an internal control could have been added to this
model by injection of an equal number of non-activated
hPBMCs or Matrigel alone in the contralateral shoulder of
the animal. In a previous study in mice, however, we
observed that inoculation of the Matrigel without cells al-
ready induced a strong migration of the activated hPBMC to
the contralateral shoulder [22]. This cell migration caused a
variable decrease of the activated PBMC in the inoculation
site. Consequently, injection of a control xenograft would
not allow us to have an exact estimation of the number of
CD25-positive cells present in the inflammatory lesion and
thus would hamper correlation of tracer accumulation with
the number of CD25-positive cells.
Although the model used in this study does not represent
all aspects of inflammation, it is an ideal model for the
validation of the quantitative analysis of activated T lym-
phocytes using [18F]FB-IL2 PET. Other animal models of
inflammation may better mimic disease processes, but do
not allow exact quantification of the number of CD25-
positive cells and can only give an indirect and inaccurate
estimation of the number of cells present in the inflamma-
tory lesion. Therefore, these more physiological animal
models do not allow accurate correlation of the PET signal
with the number of CD25 cells. A complicating factor in our
xenograft animal model could be the involvement of host
immune cells. To avoid interference of the host immune
response, the interval between inoculation and PET imaging
was therefore kept as short as possible.
Uptake of [18F]FB-IL2 in the region of inoculated acti-
vated hPBMC, measured ex vivo as SUV, increased with the
number of inoculated CD25-positive cells and an excellent
correlation between these parameters was found (R200.90).
MicroPET images showed clear [18F]FB-IL2 uptake at
the cell inoculation site, even for the smallest number of
injected cells (165,000 cells). A moderate correlation was
found between the number of CD25-positive cells and the
SUV determined from PET data (R200.56). This correlation
obtained from the imaging study was substantially lower
than the one from the ex vivo studies. This discrepancy
might be explained by partial volume effects, which can
underestimate the uptake in small or heterogeneous target
regions. In this study, inflammatory lesions were relatively
small (injection volume 0.2 ml), when compared to the
spatial resolution of the PET camera (1.35 mm full-width
at half-maximum). In addition, inflammatory lesions could
be heterogeneous, because of the inhomogeneous presence
of the Matrigel in the subcutaneous layer where the hPBMC
are trapped. Furthermore, the inflammatory lesions are ir-
regularly shaped. The inhomogeneity and irregular shape of
the lesion could lead to differences in influence of the partial
volume effect between lesions. Moreover, inflammation is a
process that involves several changes in the inflammatory
lesion, such as change in tissue perfusion and vessel perme-
ability, which can reduce the usefulness of SUVs. Therefore,
pharmacokinetic modelling might be required for accurate
quantification of lymphocyte infiltration.
For the pharmacokinetic modelling, we used the total [18F]
FB-IL2 plasma TAC without correction for tracer metabolites
as the input function, since [18F]FB-IL2 was highly stable in
plasma. More than 97 % of the tracer remained intact in
plasma 60 min p.i. In contrast, only radioactive metabolites
were found in urine. This suggests that [18F]FB-IL2 is metab-
olized by the kidneys and subsequently secreted into the urine.
This observation is in agreement with the fate of intravenously
injected native IL-2, which is also cleared into the urine after
renal tubular catabolism [27].
Because the tracer is directly injected into the systemic
circulation, the peak of the activity concentration in plasma
of [18F]FB-IL2 reaches its maximum value within 15 s after
tracer injection and then drops progressively. The plasma
[18F]FB-IL2 concentration initially declines quite rapidly
with an α phase of 0.71±0.29 min due to the elimination
from the plasma and the distribution of the tracer in tissue.
The elimination of tracer from plasma is described by a β
phase with a half-life of 8.4±2.6 min. In contrast to the
plasma curves, the TACs of the inflammatory lesion show a
clearance half-life of 37±4 %. These data suggest that after
an initial nonspecific distribution of the tracer to the entire
body of the animal [18F]FB-IL2 is retained in the inflamma-
tory lesion because of the presence of target cells that over-
express the IL-2R.
Logan and Patlak analysis are simple graphical methods
to estimate reversible and irreversible binding of a tracer to
the target, respectively. We used these methods to study the
binding characteristics of [18F]FB-IL2. The TACs of the
hPBMC xenografts showed a better fit with Logan analysis
than with the Patlak analysis method, indicating that binding
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between [18F]FB-IL2 and the IL-2R could be reversible.
Compartment modelling showed that the kinetics of [18F]
FB-IL2 are best described by a 2TCMR. However, the
volume of distribution derived from Logan, 1TCMR or
2TCMR showed only moderate correlations with the cell
number present in the inflammatory lesion. In contrast, BPs
are strongly correlated with the number of CD25-positive
cells present in the inflammatory lesion (R200.88). The BP
increases proportionally with the increase of the number of
activated hPBMC in the inflammatory region, suggesting
that with this method changes in the number of activated
hPBMC should be easily detectable.
Despite the fact that we did not include a control lesion in
the contralateral side, we were still able to estimate the
amount of nonspecific uptake at the inflammatory lesion
from the correlations of the tracer uptake with the number
of CD25-positive cells. In fact, Figs. 3 and 6 show that both
the curves of the SUV and the distribution volume as func-
tions of the number of CD25-positive cells do not cross the
y-axis at the origin, indicating that an SUVof approximately
0.17 and a distribution volume of 0.5 are due to nonspecific
uptake (i.e. in case the number of CD25-positive cells is 0).
However, when the tracer uptake is expressed as the BP the
nonspecific binding is negligible, as the curve in Fig. 7
almost crosses the y-axis at the origin. This again stresses
the importance of pharmacokinetic modelling to compen-
sate for nonspecific effects on tracer uptake.
Taken together, our data clearly demonstrate that [18F]
FB-IL2 BP is a better measure of activated hPBMC in the
inflammatory lesion than the distribution volume or SUV.
Both the distribution volume and the SUV depend not only
on the binding characteristics of the tracer to IL-2R, but also
on the perfusion of the tracer into the lesion. In contrast, BP
is independent of tracer influx (K1) and efflux (k2), but only
depends on the ratio of receptor binding and release.
Besides accuracy, sensitivity is also an important property
of a diagnostic tool. Therefore, we determined the LOD of
[18F]FB-IL2 PET and demonstrated that this technique can
detect reliably as little as 160,000 CD25+ cells, if the radio-
pharmaceutical uptake is determined as BP. Moreover, this
method is also sensitive with respect to detection of differ-
ences in CD25+ cell number. A difference in the number of
CD25+ cells of 1 million leads to a difference in 4 BP units.
Conclusion
In conclusion, the kinetics of [18F]FB-IL2 in an inflammatory
lesion is well described by Logan graphical analysis and com-
partment modelling with a 2TCMR. Since [18F]FB-IL2 is
stable in plasma, total plasma radioactivity without correction
for metabolites can be used as the input function. Because of
the high correlation between the BP and the number of CD25-
positive cells in the inflammatory lesion, infiltration of
activated hPBMC can be best quantified by measuring the BP
with [18F]FB-IL2 PET. Quantification of the tracer uptake as
SUVor distribution volume is less accurate, as these parameters
are not only dependent on receptor binding characteristics, but
also on perfusion effects. The results of this study indicate that
[18F]FB-IL2 PET could provide hitherto unavailable opportu-
nities to assess lymphocytic infiltration in inflammatory dis-
eases in a non invasive and quantitative manner. The technique
is likely sensitive enough to detect even low numbers of
infiltrating lymphocytes or small changes in the inflammatory
response.
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